Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by University of Colorado, Denver
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT01192828
First received: August 30, 2010
Last updated: October 13, 2014
Last verified: October 2014

August 30, 2010
October 13, 2014
January 2010
June 2015   (final data collection date for primary outcome measure)
  • Biomarkers associated with oxidative stress and inflammation;tumor necrosis factor (TNF)-alpha and thiobarbituric acid reactive substances (TBARS) [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
  • Pharmacokinetics of Taurine [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
  • Biochemical and Clinical Safety Data [ Time Frame: During study and 2 weeks after completion ] [ Designated as safety issue: Yes ]
See if biomarkers associated with oxidative stress and inflammation are increased in individuals with Cystathionine beta-synthase deficient homocystinuria (CBSDH) [ Time Frame: unknown ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01192828 on ClinicalTrials.gov Archive Site
  • Blood vessels and platelet function study [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
  • Taurine Pharmacokinetics [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
  • Multiple Biomarkers of Inflammation and Oxidative Stress [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
  • Relation to Biochemical Parameters of Homocystinuria [ Time Frame: 4 1/2 days ] [ Designated as safety issue: No ]
  • Bone Mineral Density [ Time Frame: Lifetime ] [ Designated as safety issue: No ]
  • see how blood vessels and platelets work in individuals with CHBSDH [ Time Frame: unknown ] [ Designated as safety issue: No ]
  • see if the levels of these biomarkers decrease with short-term taurine supplementation [ Time Frame: unknown ] [ Designated as safety issue: No ]
  • see if alterations of bone strength are related to levels of biomarkers of inflammation [ Time Frame: unknonwn ] [ Designated as safety issue: No ]
  • see if the levels of these biomarkers relate to the levels of homocysteine [ Time Frame: unknown ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine
Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine

Cystathionine beta-synthase deficiency is an inherited disease that results in elevation of a substance called homocysteine (Hcy) in blood and urine. Individuals with this disorder have a very high risk for developing blood clots and are at risk for developing eye and bone abnormalities. Current treatments are generally difficult to follow and can fail. Development of additional therapies has been limited by lack of understanding of how the disease works.

The purpose of this study is to see if oxidative stress and inflammation are involved in the disease process and if short-term supplementation with taurine is an effective treatment.

Funding source: FDA-OOPD

Cystathionine beta-synthase deficient homocystinuria(CBSDH) is an inherited disease that results in elevation of a substance called homocysteine(Hcy)in blood and urine. Individuals with this disorder have a very high risk for developing blood clots that can cause a stroke or other life-threatening problems. In addition, these individuals have bone and joint tissue abnormalities.

Current treatment with an extremely strict diet and medication (betaine) is very difficult to follow, and often fails. Development of additional treatment strategies has been limited by a lack of knowledge and understanding of how this disease works. Hence, there is a need to better understand what causes the blood clots and the bone and joint tissue abnormalities.

New data suggest that oxidative stress and inflammation play a central role in animals with this disease. Limited data on humans with this disease support this as well. Further, data from animals with this disease suggests that taurine, a natural body substance and food product, which is low in these patients, mitigates this effect. This study is designed to follow-up on these data.

The purpose of the study is to increase our understanding of the disease process in this disorder, and to see in a pilot study if short-term supplementation with taurine is an effective intervention. The aims of the study are to:

  1. see if substances (markers) associated with oxidative stress and inflammation are increased in individuals with CBSDH
  2. see if the levels of these markers relate to the levels of homocysteine
  3. see if the levels of these markers decrease with short-term taurine supplementation
  4. see how bood vessels and platelets (small substances in the blood that help blood clot) work in individuals with CBSDH, if their ability to work is related to levels of markers of oxidative stress and inflammation, and if taurine supplementation improves how they work
  5. see if alterations of bone strength are related to levels of markers of inflammation.

The hypotheses to be investigated are as follows:

  • Biomarkers of oxidative stress and inflammation are increased in individuals with CBSDH
  • The degree of elevation of the biomarkers of oxidative stress and inflammation is relative to the degree of elevation of homocysteine, the main accumulating substance for this disease.
  • Treatment with taurine mitigates the elevation of biomarkers of oxidative stress and inflammation.
  • Endothelial function (blood vessel function) is abnormal in individuals with CBSDH even when receiving standard therapy and is improved with taurine supplementation.
  • Chronic platelet aggregation, a variable finding in individuals with CBSDH, is mitigated with taurine supplementation.
  • Decreased bone mineral density relates to the increase in inflammatory markers in CBSDH.

In addition, baseline pharmacokinetics (how much taurine is in the blood) of oral pharmacologic doses of taurine will be developed.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Homocystinuria
Drug: taurine
Take Taurine for 4 1/2 days, two doses per day
Other Name: Not Applicable. No other names.
Experimental: Taurine
Treatment with Taurine
Intervention: Drug: taurine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
12
December 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. A confirmed biochemical, molecular, or enzymatic diagnosis of classic homocystinuria due to cystathionine beta-synthase deficiency (OMIM 236200)
  2. And not fully responsive to therapy (eg, total homocysteine (tHcy) levels above 50 µmol/L on therapy including on B6 therapy)
  3. Be over 8 years old and less than 50 years. The first four patients will be adults (age 18-50 years)
  4. Be able and willing to provide informed consent

Exclusion Criteria:

  1. Age less than 8 years: Individuals under 8 years of age will be excluded due to blood volume issues and concerns regarding their ability to assent
  2. Age greater than 50 years: Individuals over 50 years will be excluded due to possible age related differences in markers of oxidative stress and inflammation
  3. Pregnancy: Females who are pregnant or lactating will be excluded from the study as the influence of pregnancy on the markers is not known nor is the safety of taurine supplementation in pregnancy.
  4. Continued antioxidant intake:

    1. Individuals currently taking taurine, over the counter energy drinks containing taurine or other high dose antioxidants and unwilling to discontinue this for the study period (including a 2 week wash out period) will be excluded as such intake will likely impact laboratory results.
    2. Individuals taking Vitamin C as a prescribed treatment for their homocystinuria will be excluded as the antioxidant therapy may impact antioxidant and inflammation markers. (As Vitamin C is not standard of care for this disease we anticipate this to have minimal impact on recruitment.)
    3. Individuals currently taking platelet aggregation inhibitors such as salicylate on a self prescribed basis and unwilling to discontinue this for the study period (including a washout period of at least two weeks prior to the study) will be excluded as salicylate intake will impact platelet study results. Individuals taking salicylate (or other platelet aggregation inhibitors) prescribed as a therapy for their homocystinuria or other health issues will not be asked to stop the medication. They will participate in the study, but will be excluded only from the platelet studies.
  5. Medication interactions: Individuals unable or unwilling to abstain from use of cyclic guanosine monophosphate (cGMP) phosphodiesterase 5 inhibitors (such as Viagra) during the study period will be excluded from the nitroglycerin-induced flow-mediated dilatation studies in accordance with known labeling contraindications.
  6. Inflammatory status:

    1. Individuals who have a significant chronic illness that has a marked inflammatory component will be excluded from the study as the illness will impact inflammatory markers.
    2. Patients with an acute illness, which may impact inflammatory biomarkers, will be postponed for study entry until the acute illness is resolved. Entry into the study at a later day will be offered.
  7. Recent cardiovascular event. Cardiovascular events (stroke, myocardial infarct, deep vein thrombosis, pulmonary embolus, thrombosis, or uncontrolled hypertension) may interfere with platelet function studies and with various mediators during the first months after the event. Patients who had such an event within the last 6 months will be excluded.
  8. Hypertriglyceridemia. Individuals with a triglyceride level above 300 mg/dl will be excluded from the study.
  9. Informed consent: Individuals who are unwilling or unable to consent, or in the case of minors who are unwilling or unable to assent will be excluded due to lack of ability to ensure informed consent.
  10. Study compliance and integrity: Individual who anticipate an inability to comply with study procedures and requirements will be excluded.

    -

Both
8 Years to 49 Years
No
Contact: Cynthia Freehauf, RN CGC 303-724-2342 cynthia.freehauf@childrenscolorado.org
Contact: Johan Van Hove, MD PhD MBA 303-724-2365 johan.vanhove@childrenscolorado.org
United States
 
NCT01192828
08-1376, FDR003907
No
University of Colorado, Denver
University of Colorado, Denver
Not Provided
Principal Investigator: Johan VanHove, MD PhD MBA University of Colorado, Denver
University of Colorado, Denver
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP